The Lancet Neurology in conversation with

Explore the latest breakthroughs in brain health and neurological disease through interviews with leading researchers, neurologists, and policy experts. Each episode breaks down complex topics for a broad audience, translating cutting-edge science into practical insights. Editors at The Lancet Neurology , the world-leading clinical neurology journal, interview the investigators at the forefront of stroke, Alzheimer’s disease, epilepsy, migraine, Parkinson’s disease, multiple sclerosis, sleep disorders, traumatic brain injury, and other neurological challenges.

The Lancet Neurology in conversation with is a health podcast hosted by Unknown Host, with 72 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts The Lancet Neurology in conversation with, a health show with 72 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #6

  Marjo van der Knaap on vanishing white matter

  Aug 12, 202617 min

  For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurology, Deputy Editor Laura Hart speaks with Professor Marjo van der Knaap (Amsterdam UMC) about her clinical trial of guanabenz in children with the leukodystrophy vanishing white matter. They unpack the integrated stress response and eIF2B pathophysiology, why guanabenz moved from mouse models into a paediatric trial, the striking effect of age of onset, unexpected hallucinations as a side-effect, and where combination therapy with eIF2B activators could take the field. Essential listening for neurologists on leukodystrophy, rare paediatric neurological disease, and translating stress-response biology into treatment. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00241-3/fulltext

  ListenShow Notes
• 

  Episode #5

  Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis

  Jul 15, 202616 min

  In this episode, Heather Brown, Senior Editor at The Lancet Neurology, chats with Jan Lünemann (University of British Columbia, Canada) and Christian Münz (University of Zürich, Switzerland) about their Rapid Review on Epstein-Barr virus (EBV) and multiple sclerosis (MS). EBV, a common herpesvirus, has been strongly implicated in development of MS, and recent mechanistic advances are providing new insights into how EBV might cause MS in some people but not others. We also discuss the potential for prevention of MS with EBV vaccines, whether therapies targeting EBV might eventually be useful for MS treatment, and important unanswered questions and next steps for the field. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00177-8/fulltext

  ListenShow Notes
• 

  Episode #4

  Hal Dietz discusses the role of genetics in spinal CSF leaks

  Jun 17, 202616 min

  In this episode of In Conversation With, Morgane Boillot, Senior Editor at The Lancet Neurology, speaks with connective tissue disorders — including Marfan syndrome — and human genetics expert Hal Dietz from Johns Hopkins Medicine (Baltimore, USA) about the genetics of spontaneous spinal CSF leaks. Together, they explore the clinical presentation, diagnosis, and current treatment of spontaneous spinal CSF leaks, and discuss genetic findings revealing rare deleterious variants in FBN2, the gene encoding fibrillin-2, in patients with type 1b leaks. The conversation covers translational and mechanistic findings — including CRISPR-Cas9 mouse models and cellular interactions with the extracellular matrix — and what these reveal about the underlying biology of fibrillin-1 and fibrillin-2-related disorders. It also addresses the potential clinical implications of these findings, and Professor Dietz shares his hopes for their use in therapeutic development. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00140-7/fulltext

  ListenShow Notes
• 

  Episode #3

  Tony Schapira on GBA1 Parkinson's disease

  Jun 16, 202626 min

  In this episode of In Conversation With, Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology, speaks with movement disorders specialist Tony Schapira from UCL’s Queen Square Institute of Neurology about GBA1-associated Parkinson’s disease. Together, they explore the genetic, clinical, and biochemical links between GBA1 variants, lysosomal function, Gaucher disease, alpha-synuclein pathology, and Parkinson’s progression. The conversation also highlights current challenges in risk prediction, biomarkers, genetic counselling, clinical management, and emerging therapeutic approaches aimed at modifying or even preventing disease. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00090-6/fulltext

  ListenShow Notes
• 

  Episode #2

  Henry Brodaty and Alice Powell on cognitive resilience and ageing

  Apr 17, 202623 minS0

  <p>Join The Lancet Neurology’s In Conversation With… as editors Elena Becker-Barroso and Laura Hart welcome Henry Brodaty and Alice Powell from the University of New South Wales (Sydney, Australia) to discuss cognitive resilience and ageing.</p> <p>This episode teases apart cognitive resilience, cognitive reserve, brain maintenance, and brain reserve; explores how social determinants, life-course factors, and vascular health shape resilience; and delves into robust measures, biomarkers, and how pathologies interact with resilience. It also covers multicomponent interventions and their transferability to low-income and middle-income countries, how clinicians should communicate risk, and the key knowledge gaps and priorities for...

  ListenShow Notes

Recent guests on The Lancet Neurology in conversation with. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.